Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience

Patrizia Zappasodi, Alessandro Corso, Catherine Klersy, Gianmatteo Pica, Silvia Mangiacavalli, Marzia Varettoni, Chiara Rusconi, Cristiana Pascutto, Mario Lazzarino

Research output: Contribution to journalArticle

Abstract

In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.

Original languageEnglish
Pages (from-to)396-402
Number of pages7
JournalEuropean Journal of Cancer
Volume42
Issue number3
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Multiple Myeloma
Epidemiology
Therapeutics
Monoclonal Gammopathy of Undetermined Significance
Recurrence
Survival
Disease-Free Survival
Bone and Bones
Drug Therapy
Pain

Keywords

  • Complications
  • Epidemiology
  • Multiple myeloma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Changes in multiple myeloma epidemiology in the last thirty years : A single centre experience. / Zappasodi, Patrizia; Corso, Alessandro; Klersy, Catherine; Pica, Gianmatteo; Mangiacavalli, Silvia; Varettoni, Marzia; Rusconi, Chiara; Pascutto, Cristiana; Lazzarino, Mario.

In: European Journal of Cancer, Vol. 42, No. 3, 02.2006, p. 396-402.

Research output: Contribution to journalArticle

@article{cc32d80159ef422491d3359ef7aef181,
title = "Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience",
abstract = "In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.",
keywords = "Complications, Epidemiology, Multiple myeloma, Survival",
author = "Patrizia Zappasodi and Alessandro Corso and Catherine Klersy and Gianmatteo Pica and Silvia Mangiacavalli and Marzia Varettoni and Chiara Rusconi and Cristiana Pascutto and Mario Lazzarino",
year = "2006",
month = "2",
doi = "10.1016/j.ejca.2005.09.031",
language = "English",
volume = "42",
pages = "396--402",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Changes in multiple myeloma epidemiology in the last thirty years

T2 - A single centre experience

AU - Zappasodi, Patrizia

AU - Corso, Alessandro

AU - Klersy, Catherine

AU - Pica, Gianmatteo

AU - Mangiacavalli, Silvia

AU - Varettoni, Marzia

AU - Rusconi, Chiara

AU - Pascutto, Cristiana

AU - Lazzarino, Mario

PY - 2006/2

Y1 - 2006/2

N2 - In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.

AB - In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.

KW - Complications

KW - Epidemiology

KW - Multiple myeloma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=31144451768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144451768&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.09.031

DO - 10.1016/j.ejca.2005.09.031

M3 - Article

C2 - 16403623

AN - SCOPUS:31144451768

VL - 42

SP - 396

EP - 402

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -